Wells Fargo & Company Editas Medicine, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 182,877 shares of EDIT stock, worth $587,035. This represents 0.0% of its overall portfolio holdings.

Number of Shares

182,877

Previous 128,852 41.93%

Holding current value

$587,035

Previous $956,000 10.67%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.67 - $7.28 $252,296 - $393,302	54,025 Added 41.93%	182,877 $854,000
Q1 2024 May 10, 2024	BUY	$7.03 - $11.07 $86,665 - $136,470	12,328 Added 10.58%	128,852 $956,000
Q4 2023 Feb 09, 2024	SELL	$6.25 - $11.11 $587,950 - $1.05 Million	-94,072 Reduced 44.67%	116,524 $1.18 Million
Q3 2023 Nov 13, 2023	SELL	$6.92 - $9.31 $39,596 - $53,271	-5,722 Reduced 2.65%	210,596 $1.64 Million
Q2 2023 Aug 15, 2023	BUY	$6.36 - $11.47 $7,517 - $13,557	1,182 Added 0.55%	216,318 $1.78 Million
Q1 2023 May 12, 2023	SELL	$7.03 - $11.53 $399,782 - $655,688	-56,868 Reduced 20.91%	215,136 $1.56 Million
Q4 2022 Feb 13, 2023	BUY	$8.32 - $13.21 $685,884 - $1.09 Million	82,438 Added 43.49%	272,004 $2.41 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $45,368 - $72,456	3,731 Added 2.01%	189,566 $2.32 Million
Q2 2022 Aug 12, 2022	BUY	$9.99 - $21.35 $182,207 - $389,402	18,239 Added 10.88%	185,835 $2.2 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $219,774 - $431,276	15,609 Added 10.27%	167,596 $3.19 Million
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $1.82 Million - $2.78 Million	-68,436 Reduced 31.05%	151,987 $4.04 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $872,068 - $1.62 Million	22,207 Added 11.2%	220,423 $9.06 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $1.78 Million - $3.22 Million	56,850 Added 40.21%	198,216 $11.2 Million
Q1 2021 May 13, 2021	SELL	$39.71 - $90.58 $391,659 - $893,390	-9,863 Reduced 6.52%	141,366 $5.94 Million
Q4 2020 Feb 09, 2021	BUY	$27.07 - $84.35 $1.81 Million - $5.64 Million	66,908 Added 79.35%	151,229 $10.6 Million
Q3 2020 Nov 05, 2020	BUY	$28.06 - $37.16 $379,707 - $502,849	13,532 Added 19.12%	84,321 $2.37 Million
Q2 2020 Aug 13, 2020	BUY	$18.5 - $34.34 $253,949 - $471,385	13,727 Added 24.06%	70,789 $2.09 Million
Q1 2020 May 14, 2020	BUY	$14.88 - $32.78 $849,082 - $1.87 Million	57,062 New	57,062 $1.13 Million

Others Institutions Holding EDIT

# of Institutions

251

Shares Held

58.7M

Call Options Held

494K

Put Options Held

417K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $221M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Editas Medicine, Inc. Transaction History